RUBY Post-Market Registry on the Jada® System

CompletedOBSERVATIONAL
Enrollment

809

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

March 31, 2022

Study Completion Date

April 30, 2022

Conditions
Postpartum Hemorrhage
Interventions
DEVICE

Jada® System

The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.

Trial Locations (16)

10029

Mount Sinai, New York

10032

Nyph/Cumc, New York

11040

Long Island Jewish Medical Center, New Hyde Park

15213

UPMC - Magee Women's Hospital, Pittsburgh

19718

ChristianaCare, Newark

25302

Charleston Area Medical Center, Charleston

29464

Charleston Birth Place, Mt. Pleasant

30501

Northeast Georgia Medical Center, Gainesville

43210

The Ohio State University, Columbus

43230

Ohio Health, Gahanna

44106

University Hospitals, Cleveland

44195

Cleveland Clinic, Cleveland

55409

Allina (Abbott Northwestern), Minneapolis

70115

Oshsner Baptist, New Orleans

84132

University of Utah, Salt Lake City

92354

Loma Linda University, Loma Linda

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alydia Health

INDUSTRY

NCT04995887 - RUBY Post-Market Registry on the Jada® System | Biotech Hunter | Biotech Hunter